Exelixis focuses on future growth despite COSMIC-313 trial challenges
At the American Society of Clinical Oncology (ASCO) Genitourinary Cancer Symposium 2025, held on 13-15 February, final results from the randomised, multicentre, double-blind, Phase III COSMIC-313 clinical trial were presented.
At the American Society of Clinical Oncology (ASCO) Genitourinary Cancer Symposium 2025, held on 13-15 February, final results from the randomised, multicentre, double-blind, Phase III COSMIC-313 clinical trial were presented.
What's Your Reaction?
